18
F-FDG PET/CT Predicts Response to HER2-directed Neoadjuvant Therapy
Radiol Imaging Cancer
.
2021 Sep;3(5):e219021.
doi: 10.1148/rycan.2021219021.
Authors
Devan Diwanji
,
Kimberly Ray
,
Nola Hylton
PMID:
34533375
PMCID:
PMC8489446
DOI:
10.1148/rycan.2021219021
No abstract available
Publication types
Comment
MeSH terms
Fluorodeoxyglucose F18*
Neoadjuvant Therapy
Positron Emission Tomography Computed Tomography*
Positron-Emission Tomography
Radiopharmaceuticals
Substances
Radiopharmaceuticals
Fluorodeoxyglucose F18
Grants and funding
T32 GM007618/GM/NIGMS NIH HHS/United States